Immatics N.V is a biotechnology business based in the US. Immatics N-V shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics N-V employs 285 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Immatics N-V
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Immatics N-V stock price (NASDAQ: IMTX)Use our graph to track the performance of IMTX stocks over time.
Immatics N-V shares at a glance
|Latest market close||$11.23|
|52-week range||$8.67 - $15.59|
|50-day moving average||$11.98|
|200-day moving average||$11.60|
|Wall St. target price||$24.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.08|
Buy Immatics N-V shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Immatics N-V stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immatics N-V price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-3.27%|
|3 months (2021-04-30)||-8.10%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Immatics N-V financials
|Revenue TTM||$31.6 million|
|Gross profit TTM||$-35,832,000|
|Return on assets TTM||-28.6%|
|Return on equity TTM||-1111.57%|
|Market capitalisation||$768.1 million|
TTM: trailing 12 months
Shorting Immatics N-V shares
There are currently 1.9 million Immatics N-V shares held short by investors – that's known as Immatics N-V's "short interest". This figure is 1.7% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting Immatics N-V shares can be evaluated.
Immatics N-V's "short interest ratio" (SIR)
Immatics N-V's "short interest ratio" (SIR) is the quantity of Immatics N-V shares currently shorted divided by the average quantity of Immatics N-V shares traded daily (recently around 92293.34939759). Immatics N-V's SIR currently stands at 20.75. In other words for every 100,000 Immatics N-V shares traded daily on the market, roughly 20750 shares are currently held short.
However Immatics N-V's short interest can also be evaluated against the total number of Immatics N-V shares, or, against the total number of tradable Immatics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immatics N-V's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immatics N-V shares in existence, roughly 30 shares are currently held short) or 0.067% of the tradable shares (for every 100,000 tradable Immatics N-V shares, roughly 67 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Immatics N-V.
Find out more about how you can short Immatics N-V stock.
Immatics N-V share dividends
We're not expecting Immatics N-V to pay a dividend over the next 12 months.
Immatics N-V overview
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate.
Stocks similar to Immatics N-V
Immatics N-V in the news
Tracking Baker Brothers Portfolio - Q1 2021 Update
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
Frequently asked questionsWhat percentage of Immatics N-V is owned by insiders or institutions?
Currently 40.634% of Immatics N-V shares are held by insiders and 41.411% by institutions. How many people work for Immatics N-V?
Latest data suggests 285 work at Immatics N-V. When does the fiscal year end for Immatics N-V?
Immatics N-V's fiscal year ends in December. Where is Immatics N-V based?
Immatics N-V's address is: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 What is Immatics N-V's ISIN number?
Immatics N-V's international securities identification number is: NL0015285941
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert